November 17, 2024
Unlike marketing authorization for pharmaceuticals, mainly regulated at the European level by EMA, pricing and reimbursement decisions in Europe are managed by individual member states. Health care services are generally covered by a single public health insurer operating under the Ministry of Health supervision. As a monopoly buyer, this situation provides a leading position for the public health insurer to set reimbursement conditions. Therefore, based on each country’s set of regulations, processes, and values, wide variations exist in pricing and reimbursement decisions of pharmaceuticals.
Using up-to-date governmental regulation sources, learn about health technology decision-making processes for reimbursement decisions for pharmaceuticals in France, Germany, Hungary, Italy, Poland, Spain, Sweden, and the UK.
You will come away from this informative course understanding these reimbursement systems, and be able to to compare and bring into contrast their key characteristics.
This short course is offered in-person at the ISPOR Europe 2024 conference.
*Conference attendance is not required to attend an ISPOR Short Course. Separate registration is required for conference attendees.
LEVEL: Intermediate
TRACK: Health Policy & Regulatory
HEOR Key Competency: 9.1 Global Understanding of Health Systems and HTA
LENGTH: 8 Hours | Course runs 1 day
FACULTY MEMBER
Schedule:
Sunday, 17 November 2024 | Course runs 1 Day
08:00-17:00 Central European Time (CET)
Register Here
*Conference attendance is not required to attend an ISPOR Short Course. Separate registration is required for conference attendees.
Visit the ISPOR Europe 2024 Program page to view all short courses offered.